Company intelligence / Profile preview
Terremoto Biosciences
San Francisco, California, United Statesterremotobio.com ↗
- Ownership
- Private
- Employees
- ~35
- Development stage
- Preclinical
01
Overview
The company aims to deliver highly targeted small molecule medicines with optimized clinical profiles using a novel lysine-based covalent approach that broadens the universe of druggable targets. They emphasize rapid delivery of these medicines to patients through their platform[1][2][5]. No detailed clinical results are available as they appear still in discovery/preclinical phases.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule medicines leveraging covalent chemistry, specifically lysine-based covalency
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Terremoto Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Terremoto Biosciences.